HLA-C and neoplasm: CAR T-cell therapies represent an promising area of innovation in the treatment of B-cell lymphomas, in which patient’s T cells are transduced with a viral vector to form a CAR, comprising a tumor-targeting antibody portion linked to TCR intracellular signal transduction domains, which bypasses MHC restrictions for tumor-cell recognition and killing (Ansell and Lin, 2020).